Compare Procter & Gamble Health with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs DIVIS LABORATORIES - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH DIVIS LABORATORIES PROCTER & GAMBLE HEALTH/
DIVIS LABORATORIES
 
P/E (TTM) x 52.7 34.6 152.2% View Chart
P/BV x 4.8 6.6 71.8% View Chart
Dividend Yield % 10.0 0.9 1,081.3%  

Financials

 PROCTER & GAMBLE HEALTH   DIVIS LABORATORIES
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
DIVIS LABORATORIES
Mar-19
PROCTER & GAMBLE HEALTH/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3,5491,639 216.5%   
Low Rs1,3011,115 116.7%   
Sales per share (Unadj.) Rs511.4186.3 274.5%  
Earnings per share (Unadj.) Rs61.351.0 120.3%  
Cash flow per share (Unadj.) Rs74.057.3 129.1%  
Dividends per share (Unadj.) Rs440.0016.00 2,750.0%  
Dividend yield (eoy) %18.11.2 1,561.6%  
Book value per share (Unadj.) Rs927.8261.8 354.4%  
Shares outstanding (eoy) m16.60265.47 6.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.77.4 64.2%   
Avg P/E ratio x39.627.0 146.4%  
P/CF ratio (eoy) x32.824.0 136.4%  
Price / Book Value ratio x2.65.3 49.7%  
Dividend payout %717.931.4 2,286.4%   
Avg Mkt Cap Rs m40,257365,592 11.0%   
No. of employees `0001.111.8 9.6%   
Total wages/salary Rs m1,3135,423 24.2%   
Avg. sales/employee Rs Th7,486.74,175.1 179.3%   
Avg. wages/employee Rs Th1,157.6457.7 252.9%   
Avg. net profit/employee Rs Th897.21,141.8 78.6%   
INCOME DATA
Net Sales Rs m8,49049,463 17.2%  
Other income Rs m2441,556 15.7%   
Total revenues Rs m8,73451,019 17.1%   
Gross profit Rs m1,48218,718 7.9%  
Depreciation Rs m2111,689 12.5%   
Interest Rs m035 0.0%   
Profit before tax Rs m1,51418,551 8.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5635,023 11.2%   
Profit after tax Rs m1,01713,527 7.5%  
Gross profit margin %17.537.8 46.1%  
Effective tax rate %37.127.1 137.2%   
Net profit margin %12.027.3 43.8%  
BALANCE SHEET DATA
Current assets Rs m15,34346,501 33.0%   
Current liabilities Rs m1,9608,468 23.1%   
Net working cap to sales %157.676.9 205.0%  
Current ratio x7.85.5 142.5%  
Inventory Days Days49131 37.3%  
Debtors Days Days2886 33.1%  
Net fixed assets Rs m1,20925,797 4.7%   
Share capital Rs m166531 31.3%   
"Free" reserves Rs m15,23568,962 22.1%   
Net worth Rs m15,40169,493 22.2%   
Long term debt Rs m00-   
Total assets Rs m17,59580,383 21.9%  
Interest coverage xNM531.0-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 78.4%   
Return on assets %5.816.9 34.3%  
Return on equity %6.619.5 33.9%  
Return on capital %10.326.7 38.4%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m1,63641,238 4.0%   
Fx outflow Rs m4,36812,405 35.2%   
Net fx Rs m-2,73228,833 -9.5%   
CASH FLOW
From Operations Rs m-1,3049,543 -13.7%  
From Investments Rs m12,697-6,854 -185.3%  
From Financial Activity Rs m-301-2,459 12.2%  
Net Cashflow Rs m11,093230 4,831.4%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 11.8 154.2%  
FIIs % 1.0 19.0 5.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.2 169.2%  
Shareholders   28,591 31,796 89.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON   PFIZER  ALKEM LABORATORIES  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 18, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - ASTRAZENECA PHARMA COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS